Qyuns Therapeutics (02509) disclosed a share repurchase undertaken on 30 January 2026. According to the announcement, 91,200 shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 20.96 to HKD 21.9, with a total consideration of approximately HKD 1,957,252.32. These shares are classified as treasury shares, increasing the total treasury share count to 2,197,000 as of that day.

The total number of issued shares remains at 227,071,600, while the number of issued shares excluding treasury shares stands at 224,874,600. The repurchase is subject to a mandate approved on 20 June 2025, which authorizes up to 22,207,160 shares for repurchase. Under the mandate, there is a moratorium period restricting any new share issuance or sale or transfer of treasury shares until 1 March 2026, as per listing rules.